What is the 13F Pro Quality Score for TCRX?

13F Pro ranks TScan Therapeutics, Inc. (TCRX) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View TCRX's current score at https://13fpro.ai/research/TCRX (free sign-up required for the full ranking).

Which hedge funds own the most TCRX stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of TCRX include Lynx1 Capital Management, BVF /IL, BAKER BROS. ADVISORS. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/TCRX as soon as new 13F filings post.

Where does 13F Pro source TCRX data?

All TScan Therapeutics, Inc. fundamentals and ownership data come directly from SEC EDGAR. TScan Therapeutics, Inc. files with the SEC under CIK 1783328. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is TCRX in?

TScan Therapeutics, Inc. (TCRX) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is TCRX research updated on 13F Pro?

TCRX's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

TScan Therapeutics, Inc.(TCRX)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1783328 TCRX stock profile & AI dashboard →

13F Pro Quality Score

8.7/100

Rank #2,822 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

5.7/100

Profitability

1.8/100

Balance Sheet

2.4/100

Earnings Quality

30.0/100

Free Cash Flow

1.7/100

Institutional Flow

88.8/100

Revenue Scale

3.2/100

Dilution Risk

2.9/100

TCRX Stock Analysis & AI Quality Score

AI stock analysis and institutional research for TScan Therapeutics, Inc. (TCRX), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores TCRX at 8.7/100 on a 32-signal composite quality model, placing it at rank #2,822 of 2,879 stocks — the bottom half of the AI-ranked universe. TCRX scores in the top quartile across institutional flow (88.8). Areas of concern include free cash flow (1.7) and profitability (1.8), which score below median versus the broader universe. Shareholder dilution risk is elevated at 2.9/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), TScan Therapeutics, Inc. reports quarterly revenue of $982.0K, net income of $-28.7M, free cash flow of $-24.3M. Top institutional holders of TCRX by reported 13-F value include Lynx1 Capital Management, BVF /IL, BAKER BROS. ADVISORS, based on the most recent SEC filings. TCRX trades on the Nasdaq exchange and files with the SEC under CIK 1783328. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate TCRX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for TScan Therapeutics, Inc. directly from SEC EDGAR. TScan Therapeutics, Inc.'s 13F Pro composite quality score has ranged between 4 and 27 since 2022, currently 8.7 — a declining long-term trajectory across 24 quarterly and live scoring snapshots.

✦

Fun facts about TScan Therapeutics, Inc.

Quirks, history, and lore behind TCRX — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. clinical-stage biopharmaceutical company · listed on Nasdaq · headquartered in Cambridge, Massachusetts · focused on cancer immunotherapy.
2
The Numbers
Like most clinical-stage biotechs, it carries no product revenue and burns through cash funding research — a small-cap company where the pipeline is the entire story.
3
The History
Founded in the late 2010s and went public around 2021, riding the wave of enthusiasm for next-generation T cell-based cancer treatments.
4
The Secret
Its core platform is built around identifying which T cell receptors recognize cancer antigens — essentially teaching the immune system to hunt tumors by their molecular fingerprints.
5
The Lore
The company's name is basically a confession: it is entirely dedicated to T cell receptor biology, the same immune machinery that makes CAR-T therapy tick — just approached from a different angle.
6
The Giveaway
Its ticker is literally TCRX — T Cell Receptor, spelled out — and its platform is called TScan, because it scans for the exact receptors that recognize your tumor.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q1 2026

$982.0K

Net Income

Q1 2026

$-28.7M

Free Cash Flow

Q1 2026

$-24.3M

D/E Ratio

Q1 2026

0.34

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

-50.9% YoY

$10.3MFY 2025

FY21 $10.1MFY22 $13.5MFY23 $21.0MFY25 $10.3M

Net Income

-45.4% YoY

$-129.8MFY 2025

FY21 $-48.6MFY22 $-66.2MFY23 $-89.2MFY25 $-129.8M

Operating Income

-45.3% YoY

$-135.8MFY 2025

FY21 $-48.6MFY22 $-66.6MFY23 $-93.5MFY25 $-135.8M

EPS (Diluted)

+26.5% YoY

$-1.00FY 2025

FY21 $-4.17FY22 $-2.75FY23 $-1.36FY25 $-1.00

Total Assets

-15.9% YoY

$228.8MFY 2025

FY21 $188.1MFY22 $199.1MFY23 $272.1MFY25 $228.8M

Total Debt

-2.6% YoY

$32.5MFY 2025

FY21 —FY22 $29.3MFY23 $33.4MFY25 $32.5M

Op. Cash Flow

-120.5% YoY

$-135.3MFY 2025

FY21 $-48.7MFY22 $-66.5MFY23 $-61.4MFY25 $-135.3M

Metric	FY 2025	FY 2023	FY 2022	FY 2021
Revenue	$10.3M -50.9%	$21.0M +55.5%	$13.5M +33.5%	$10.1M
Net Income	$-129.8M -45.4%	$-89.2M -34.7%	$-66.2M -36.2%	$-48.6M
Operating Income	$-135.8M -45.3%	$-93.5M -40.3%	$-66.6M -37.0%	$-48.6M
EPS (Diluted)	$-1.00 +26.5%	$-1.36 +50.5%	$-2.75 +34.1%	$-4.17
Total Assets	$228.8M -15.9%	$272.1M +36.7%	$199.1M +5.8%	$188.1M
Total Debt	$32.5M -2.6%	$33.4M +14.0%	$29.3M	—
Operating Cash Flow	$-135.3M -120.5%	$-61.4M +7.7%	$-66.5M -36.6%	$-48.7M

AI Insight: TCRX Financial Trends

Revenue growth momentum stalled while cash burn remained elevated, with equity declining from $255M to $97M over eight quarters.

• Revenue increased from $1M in Q2 2024 to $3M in Q4 2025 before dropping back to $1M in Q1 2026.

• Total equity declined consistently from $255M in Q2 2024 to $97M in Q1 2026.

• Operating losses improved from $-37M in Q4 2024 to $-24M in Q4 2025.

• Total debt decreased from $41M in Q2 2024 to $33M in Q1 2026.

⚠ Revenue volatility with Q1 2026 dropping to $1M from $3M in prior quarters.

⚠ Operating cash flow worsened to $-38M in Q1 2025 before improving to $-24M in Q1 2026.

AI Insight: TCRX Ratio Trends

TScan's profitability deteriorated sharply with ROE declining from -49.6% in Q2 2024 to -118.3% in Q1 2026.

• ROE deteriorated from -49.6% in Q2 2024 to -118.3% in Q1 2026, indicating worsening losses relative to equity.

• ROIC declined from -46.1% in Q2 2024 to -90.0% in Q1 2026, showing poor capital efficiency.

• Debt-to-equity ratio more than doubled from 0.15 in Q4 2024 to 0.34 in Q1 2026.

⚠ TTM ROE of -128.2% is worse than Q1 2026's -118.3%, suggesting recent quarterly losses may be understating full-year impact.

⚠ Rising leverage amid deteriorating profitability could strain financial flexibility for this biotech company.

Get alerted when TCRX's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for TScan Therapeutics, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of TCRX

Lynx1 Capital Management LP
$8.1M8,019,148 sh
BVF INC/IL
$5.6M5,564,290 sh
BAKER BROS. ADVISORS LP
$2.8M2,784,792 sh
VANGUARD CAPITAL MANAGEMENT LLC
$2.2M2,154,256 sh
BlackRock, Inc.
$1.9M1,840,952 sh
MILLENNIUM MANAGEMENT LLC
$1.5M1,460,285 sh
RENAISSANCE TECHNOLOGIES LLC
$1.4M1,364,783 sh
Deer Management Co. LLC
$1.3M1,245,504 sh
TWO SIGMA INVESTMENTS, LP
$1.2M1,209,009 sh
abrdn plc
$927.2K918,020 sh

Fund	Value	Shares
Lynx1 Capital Management LP	$8.1M	8,019,148
BVF INC/IL	$5.6M	5,564,290
BAKER BROS. ADVISORS LP	$2.8M	2,784,792
VANGUARD CAPITAL MANAGEMENT LLC	$2.2M	2,154,256
BlackRock, Inc.	$1.9M	1,840,952
MILLENNIUM MANAGEMENT LLC	$1.5M	1,460,285
RENAISSANCE TECHNOLOGIES LLC	$1.4M	1,364,783
Deer Management Co. LLC	$1.3M	1,245,504
TWO SIGMA INVESTMENTS, LP	$1.2M	1,209,009
abrdn plc	$927.2K	918,020

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put TCRX on your watchlist

Track score changes the day TScan Therapeutics, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is TCRX a good stock to buy?

13F Pro's AI-powered analysis of TScan Therapeutics, Inc. (TCRX) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for TCRX are available on the TCRX stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own TCRX?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling TCRX. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of TScan Therapeutics, Inc.'s investment landscape.